GlassScriptPhysician profile
Julie Hitzges
NPI 1598322638
$1,722.70
in general payments reported to CMS, 2019-2025
22 companies · $81.92 in 2025
The $81.92 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $168 · 2022: $262 · 2023: $764 · 2024: $448 · 2025: $81.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.97 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $448.49 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $278.41 | 2021-2025 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $121.17 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $105.58 | 2023-2025 | |
| Gilead Sciences, INC. | $90.00 | 2022 | |
| Currax Pharmaceuticals LLC | $65.06 | 2023-2024 | Nexletol, Contrave |
| Exact Sciences Corporation | $57.80 | 2023 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $55.64 | 2023-2024 | Sapien 3 Ultra Resilia |
| Shield Therapeutics INC | $48.82 | 2023 | Accrufer |
| Abbvie INC. | $46.60 | 2022-2023 | |
| Amgen INC. | $39.40 | 2023-2024 | Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $35.06 | 2023-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $35.01 | 2022-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.25 | 2024 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.36 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.14 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $23.34 | 2023 | Rexulti |
| Insulet Corporation | $17.83 | 2023 | Omnipod |
| Mylan Specialty L.P. | $17.14 | 2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $16.10 | 2023 | Farxiga |
| Phathom Pharmaceuticals, INC. | $15.50 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Hitzges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.